# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001654954-23-002518
**Filing Date:** 2023-3
**Character Count:** 10904
**Document Hash:** dee8db007075f21b405ad351cb5259f4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-23-002518.hdr.sgml**: 20230308

**ACCESSION NUMBER**: 0001654954-23-002518

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230308

**FILED AS OF DATE**: 20230308

**DATE AS OF CHANGE**: 20230308

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 23714825

**BUSINESS ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of March 2023

Commission File Number: 001-11960

 **AstraZeneca PLC**

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

 **AstraZeneca PLC**

INDEX TO EXHIBITS

***1. Director/PDMR Shareholding***

8 March 2023 11:01 GMT

 **Transactions by Persons Discharging Managerial Responsibilities**

AstraZeneca PLC (the Company) announced that, on 4 March 2023, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **PDMR** | **Position** | **Ordinary Shares granted under the AZDBP** | **Ordinary Shares granted under the AZPSP** | **Award price per Ordinary Share** |
| Pascal Soriot | Executive Director and Chief Executive Officer | 14448 | 85808 | £108.21 |
| Aradhana Sarin | Executive Director and Chief Financial Officer | 7403 | 38046 | £108.21 |

---

The AZDBP award represents the portion of each PDMR's annual bonus for 2022 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.

The AZPSP award is subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance. The performance measures will be assessed over a three-year performance period (1 January 2023 to 31 December 2025). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.

Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2022, which is available on the Company's website at <u>www.astrazeneca.com/annualreport202</u><u>2</u>.

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).

---

| | | | |
|:---|:---|:---|:---|
| **1**<br>| **Details of the person discharging managerial responsibilities / person closely associated** | **Details of the person discharging managerial responsibilities / person closely associated** | **Details of the person discharging managerial responsibilities / person closely associated** |
| a)<br>| Name | Pascal Soriot | Pascal Soriot |
| **2**<br>| **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a)<br>| Position/status<br>| Chief Executive Officer | Chief Executive Officer |
| b)<br>| Initial notification /Amendment | Initial notification | Initial notification |
| **3**<br>| **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a)<br>| Name | AstraZeneca PLC | AstraZeneca PLC |
| b)<br>| LEI | PY6ZZQWO2IZFZC3IOL08 | PY6ZZQWO2IZFZC3IOL08 |
| **4i**<br>| **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** |
| a)<br>| Description of the financial instrument, type of instrument<br>Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC<br>GB0009895292 | Ordinary Shares of US$0.25 each in AstraZeneca PLC<br>GB0009895292 |
| b)<br>| Nature of the transaction<br>| Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan | Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan |
| c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| c) | Price(s) and volume(s) | £108.21<br>| 100256 |
| d)<br>| Aggregated information<br>- Aggregated volume<br> - Price | Not applicable - single transaction | Not applicable - single transaction |
| e)<br>| Date of the transaction<br>| 4 March 2023 | 4 March 2023 |
| f)<br>| Place of the transaction<br>| Outside a trading venue | Outside a trading venue |

---

---

| | | | |
|:---|:---|:---|:---|
| **1**<br>| **Details of the person discharging managerial responsibilities / person closely associated** | **Details of the person discharging managerial responsibilities / person closely associated** | **Details of the person discharging managerial responsibilities / person closely associated** |
| a)<br>| Name | Aradhana Sarin | Aradhana Sarin |
| **2**<br>| **Reason for the notification** | **Reason for the notification** | **Reason for the notification** |
| a)<br>| Position/status<br>| Chief Financial Officer | Chief Financial Officer |
| b)<br>| Initial notification/Amendment | Initial notification | Initial notification |
| **3**<br>| **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** | **Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor** |
| a)<br>| Name | AstraZeneca PLC | AstraZeneca PLC |
| b)<br>| LEI | PY6ZZQWO2IZFZC3IOL08 | PY6ZZQWO2IZFZC3IOL08 |
| **4i**<br>| **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** | **Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted** |
| a)<br>| Description of the financial instrument, type of instrument<br>Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC<br>GB0009895292 | Ordinary Shares of US$0.25 each in AstraZeneca PLC<br>GB0009895292 |
| b)<br>| Nature of the transaction<br>| Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan | Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan |
| c) | Price(s) and volume(s) | Price(s)<br>| Volume(s) |
| c) | Price(s) and volume(s) | £108.21<br>| 45449 |
| d)<br>| Aggregated information<br>- Aggregated volume<br> - Price | Not applicable - single transaction | Not applicable - single transaction |
| e)<br>| Date of the transaction<br>| 4 March 2023 | 4 March 2023 |
| f)<br>| Place of the transaction<br>| Outside a trading venue | Outside a trading venue |

---

 **AstraZeneca**

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit <u>astrazeneca.com</u> and follow the Company on Twitter <u>@AstraZeneca</u>.

 **Contacts**

For details on how to contact the Investor Relations Team, please click <u>here</u>. For Media contacts, click <u>here</u>.

 **Adrian Kemp**

 **Company Secretary**

 **AstraZeneca PLC**

 <u>SIGNATURES</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 08 March 2023

---

| |
|:---|
| By: /s/ Adrian Kemp |
| Name: Adrian Kemp |
| Title: Company Secretary |

---